Clene Inc.

Equities

CLNN

US1856341029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-26 EDT			5-day change	1st Jan Change
0.3511 ^USD	-2.47%		-7.63%	+18.37%

06-21	Clene Says Lead Drug Candidate Shows Potential to Treat Rett Syndrome	MT
06-21	Clene Inc. and Clene Nanomedicine Inc. Present Preliminary Data for CNM-Au8 as Potential Treatment for Rett Syndrome	CI

Clene Inc. Ratifies the Appointment of Deloitte & Touche LLP as Independent Registered Public Accounting Firm for Fiscal Year 2024

May 30, 2024 at 05:16 pm

Clene Inc. announced at annual meeting of shareholders held on May 29, 2024, the shareholders ratified the appointment of Deloitte & Touche LLP as the Company?s independent registered public accounting firm for fiscal year 2024.

Latest news about Clene Inc.

Clene Says Lead Drug Candidate Shows Potential to Treat Rett Syndrome	06-21	MT
Clene Inc. and Clene Nanomedicine Inc. Present Preliminary Data for CNM-Au8 as Potential Treatment for Rett Syndrome	06-21	CI
Clene Inc. and Clene Nanomedicine, Inc. Present Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8 30 mg	06-18	CI
Clene Inc. Ratifies the Appointment of Deloitte & Touche LLP as Independent Registered Public Accounting Firm for Fiscal Year 2024	05-30	CI
Earnings Flash (CLNN) CLENE Reports Q1 Revenue $73M	05-08	MT
Clene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension Study Results at the 2024 American Academy of Neurology Annual Meeting in Denver	04-16	CI
Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8	03-15	CI
Clene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI
North American Morning Briefing : Stock Futures -2-	03-11	DJ
Clene Reports Significant Survival Benefit with Cnm-Au8® Treatment in Als Eap Compassionate Use Programs	02-22	CI
Clene Inc. Reports Significant Improvement in Vision and Cognition with Cnm-Au8®? Treatment in Vision-MS Trial	01-08	CI
US FDA finds Clene's trial data for ALS drug to be insufficient	12-21	RE
Clene Inc. and Clene Nanomedicine Inc. Announce Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement in Neurodegenerative Diseases	12-14	CI
Earnings Flash (CLNN) CLENE Reports Q3 Revenue $108M	11-07	MT
Clene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
North American Morning Briefing : Stocks Look to -2-	11-06	DJ
Sector Update: Health Care Stocks Advancing Late Afternoon	23-10-05	MT
Sector Update: Health Care	23-10-05	MT
Clene Shares Jump After Being Awarded $45.1 Million Government Grant for Investigational ALS Drug	23-10-05	MT
Clene Awarded $45.1 Million Government Grant to Fund EAP for Investigational ALS Drug	23-10-05	MT
Clene Files for Potential Secondary Offering of Up to 3 Million Common Shares	23-09-25	MT
Clene Inc. Announces Executive Changes	23-09-19	CI
Certain Warrants of Clene Inc. are subject to a Lock-Up Agreement Ending on 15-SEP-2023.	23-09-14	CI
Certain Stock Options of Clene Inc. are subject to a Lock-Up Agreement Ending on 15-SEP-2023.	23-09-14	CI

Chart Clene Inc.

Duration

Period

More charts

Company Profile

Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis. It specializes in the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its CNM-Au8 is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide pathway while reducing oxidative stress. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for treatment of infectious diseases and to support wound healing.

Sector

Biotechnology & Medical Research

Calendar

07:00am - H.C. Wainwright Neuro Perspectives Virtual Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Clene Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.36 USD

Average target price

5 USD

Spread / Average Target

+1,288.89%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CLENE INC.	+18.37%	46.24M
VERTEX PHARMACEUTICALS INCORPORATED	+16.49%	122B
REGENERON PHARMACEUTICALS, INC.	+21.73%	116B
ARGENX SE	+22.18%	27.03B
BIONTECH SE	-21.81%	20.36B
GENMAB A/S	-16.89%	16.43B
BEIGENE, LTD.	-18.81%	15.91B
WUXI APPTEC CO., LTD.	-44.74%	15.6B
SAREPTA THERAPEUTICS, INC.	+62.72%	14.94B
NEUROCRINE BIOSCIENCES, INC.	+3.09%	13.59B

Bio Therapeutic Drugs